Nestec S.a.

Societe Des Produits Nestle S.a.

Sunil Kochhar

Francois-Pierre Martin

Serge Andre Dominique Rezzi

Sebastiano Collino

Norbert Sprenger

Marcel Alexandre Juillerat

Marie-Claire Fichot

Jeremy Kirk Nicholson

Marc-Emmanuel Dumas

Serge Rezzi

Claire L Boulange

Ivan Montoliu Roura

Carl Erik Hansen

Yuanlong Pan

Michael Affolter

James Gerard McCarthy

Irène Corthesy-Theulaz

Elaine Holmes

Francia Jacqueline Arce Vera

Peter Van Bladeren

Marcel-Alexandre Juillerat

François-Pierre Martin

Martin Grigorov

Ivan Montoliu Rora

Carl Eric Hansen

Christopher Budwig

Emma Peré-Trepat

Laurent-Bernard Fay

Jean-Claude Spadone

Peter Kastenmayer

Serge André Dominique Rezzi

Françoise-Pierre Martin

Ulrich Zachariae

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be trimethylamine-N-oxide.

Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine.

Isovalerylglycine as biomarker for the predispositon for weight gain and obesity

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be hexanoylglycine.

Hexanoylglycine as biomarker for the predisposition for weight gain and obesity

The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.

Methods for preventing or treating sarcopenia and muscle atrophy in animals

A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.

Nutritional composition containing oligosaccharide mixture

A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.

The present invention pertains to novel cocoa polypeptides having a molecular weight of about 10 and 14 kDa and being derived from a 69 kDa precursor. In particular, the present invention relates to the production of the polypeptides via recombinant means and the use of the polypeptides or fragments thereof for the production of cocoa/chocolate flavor.

Cocoa polypeptides and their use in the production of cocoa and chocolate flavor

The present invention pertains to specific peptides obtainable from cocoa beans and giving rise to a particular and distinct savor when subjected to a Maillard reaction with reducing sugars. In particular, the present invention pertains to the use of one or more of these specific peptides for the preparation of a chocolate flavor, specifically a cocoa and a caramel flavor, a floral or specifically, a bonbon flavor, a bready flavor, a roasted flavor or a meat flavor.

Flavor-active peptides

The present invention is directed to a novel 2S cocoa albumin protein that has now been isolated, purified and identified from cocoa beans. The present invention is further directed to flavor precursors generated from the enzymatic hydrolysis of this novel protein and to use of the flavor precursors to form a cocoa flavor useful in making chocolate flavored compositions.

Cocoa albumin and its use in the production of cocoa and chocolate flavor

Growing community of inventors

Savigny, Switzerland

Sunil Kochhar